Tag Archives: Jason Mccarthy
BioNano Genomics (BNGO) Gets a Buy Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BioNano Genomics (BNGO – Research Report), with a price target of $3.00. The company’s shares closed last Monday at $0.88, close to its 52-week low
Analysts Offer Insights on Healthcare Companies: ADMA Biologics (NASDAQ: ADMA), Sarepta Therapeutics (NASDAQ: SRPT) and Clovis Oncology (NASDAQ: CLVS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ADMA Biologics (ADMA – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Clovis Oncology (CLVS – Research Report) with bullish sentiments.
Galmed Pharmaceuticals (GLMD) Receives a Buy from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Galmed Pharmaceuticals (GLMD – Research Report), with a price target of $10.00. The company’s shares closed last Monday at $4.48, close to its 52-week low
Maxim Group Maintains a Buy Rating on Bellerophon (BLPH)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Bellerophon (BLPH – Research Report), with a price target of $2.00. The company’s shares closed last Monday at $0.44, close to its 52-week low of
Maxim Group Keeps a Buy Rating on Viking Therapeutics (VKTX)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of $14.00. The company’s shares closed last Monday at $7.73. According to TipRanks.com, McCarthy has currently no stars
BeiGene (BGNE) Received its Third Buy in a Row
After Morgan Stanley and Cowen & Co. gave BeiGene (NASDAQ: BGNE) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy maintained a Buy rating on BeiGene yesterday and set a price
